Drug target identification in intracellular and extracellular protozoan parasites

Current Topics in Medicinal Chemistry

Volumn 11, Issue 16, 2011, Pages 2029-2038

  Müller, Joachim ^a   Hemphill, Andrew ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

Apicoplast; Chemotherapy; Drug targets; Echinococcus; Giardia; Mechanism of action; Neospora; Plasmodium; Toxoplasma

Indexed keywords

ACRIDINE DERIVATIVE; ALBENDAZOLE; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPHOTERICIN B; ANTIPROTOZOAL AGENT; APICIDIN; CIPROFLOXACIN; CLINDAMYCIN; CLOSANTEL; DAIDZEIN; DEOXYCHOLIC ACID; ETOPOSIDE; GENISTEIN; HYGROMYCIN; INTERCALATING AGENT; ISOFLAVONE DERIVATIVE; KANAMYCIN; MEFLOQUINE; MEPACRINE; MILTEFOSINE; PAROMOMYCIN; PENTAMIDINE DERIVATIVE; PHOSPHODIESTERASE INHIBITOR; PRAZIQUANTEL; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SPIRAMYCIN; TETRACYCLINE; THIOLACTOMYCIN; TRICLABENDAZOLE; UNINDEXED DRUG;

ANTIBIOTIC RESISTANCE; ANTIPROTOZOAL ACTIVITY; APICOPLAST; ARTICLE; BINDING AFFINITY; CELL MEMBRANE; CELL STRUCTURE; CELL ULTRASTRUCTURE; DRUG DESIGN; DRUG DNA BINDING; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; GENE EXPRESSION REGULATION; GENOME ANALYSIS; GIARDIA; HUMAN; MICROBIAL METABOLISM; NEPHROTOXICITY; NONHUMAN; PLASMODIUM; PROTOZOAL INFECTION; RNA BINDING; SIGNAL TRANSDUCTION; TOXOPLASMA; TRANSCRIPTION INITIATION;

ANIMALS; ANTIPROTOZOAL AGENTS; DATABASES, GENETIC; DNA, PLANT; DNA, PROTOZOAN; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE; ECHINOCOCCUS; GENE EXPRESSION REGULATION; GENOME, PROTOZOAN; GIARDIA; HUMANS; METABOLIC NETWORKS AND PATHWAYS; MOLECULAR TARGETED THERAPY; NEOSPORA; PLASMODIUM; PLASTIDS; PROTOZOAN INFECTIONS; PROTOZOAN PROTEINS; TOXOPLASMA;

EID: 80051693290     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/156802611796575876     Document Type: Article

References (100)

1. Cassell, G. H.; Mekalanos, J. Development of antimicrobial agents in the era of new and reemerging infectious diseases and increasing antibiotic resistance. J. Am. Med. Ass., 2001, 285, 601-605.
2. Egan, T J.; Kaschula, C.H. Strategies to reverse drug resistance in malaria. Curr. Opin. Infect. Dis., 2007, 20, 598-604.
3. Gardner, T. B.; Hill, D. R. Treatment of Giardiasis. Clin. Microbiol. Rev., 2001, 14, 114-128.
4. Chavez, B.; Espinosa-Cantellano, M.; Cedillo-Rivera, R.; Ramírez, A.; Martínez-Palomo, A. Effects of albendazole on Entamoeba histolytica and Giardia lamblia trophozoites. Arch. Med. Res., 1992. 23, 63-67.
5. Müller, J.; Sterck, M.; Hemphill, A.; Müller, N. Characterization of Giardia lamblia WB C6 clones resistant to nitazoxanide and to metronidazole. J. Antimicrob. Chemother., 2007, 60, 280-287.
6. Innes, E. A; Vermeulen, A.N. Vaccination as a control strategy against the coccidial parasites Eimeria, Toxoplasma Neospora. Parasitol., 2007, 133, S145-S168.
7. McAllister, M. M. A decade of discoveries in veterinary protozoology changes our concept of "subclinical" toxoplasmosis. Vet. Parasitol., 2005, 132, 241-247.
8. Greif, G.; Harder, A.; Haberkorn, A. Chemotherapeutic approaches to protozoa: Coccidiae-current level of knowledge and outlook. Parasitol. Res., 2001, 87, 973-975.
9. Petersen, E. Prevention and treatment of congenital toxoplasmosis Exp. Rev. Antiinf. Ther., 2007, 5, 285-293.
10. Hemphill, A.; Stadelmann, B.; Scholl, S.; Müller, J.; Spiliotis, M.; Müller, N.; Gottstein, B.; Siles-Lucas, M. Echinococcus metacestodes as laboratory models for the screening of drugs against cestodes and trematodes. Parasitology, 2010, 137, 569-587.
11. Doerig, C. Protein kinases as targets for anti-parasitic chemotherapy. Biochim. Biophys. Acta, 2004, 1697, 155-168.
12. Kayser, O.; Kiderlen, A. F.; Croft, S. L. Natural products as antiparasitic drugs. Parasitol. Res., 2003, 90, S55-S62.
13. Timmers, L. F.; Pauli, I.; Barcellos, G. B.; Rocha, K. B.; Caceres, R. A.; de Azevedo, Jr W. F.; Soares, M. B. Genomic databases and the search of protein targets for protozoan parasites. Curr. Drug Targets, 2009, 10, 240-245.
14. Wang, C. C. Validating targets for antiparasite chemotherapy. Parasitology, 1997, 114, (Suppl) S31-44.
15. Ciak, J.; Hahn, F. E. Quinacrine (atebrin): mode of action. Science, 1967, 156, 655-656.
16. Wilson, W.D.; Mizan, S.; Tanious, F. A.; Yao, S.; Zon, G. The interaction of intercalators and groove-binding agents with DNA triple-helical structures: the influence of ligand structure, DNA backbone modifications and sequence. J. Mol. Recognit., 1994, 7, 89-98.
17. Bell, C.A.; Hall, J.E.; Cory, M.; Fairley, T.; Tidwell, R. R. Structure-activity relationships of pentamidine analogs against Giardia lamblia and correlation of antigiardial activity with DNA binding affinity. Antimicrob. Agents Chemother., 1991, 35, 1099-1107.
18. Bell, C.A.; Dykstra, C. C.; Naiman, N. A.; Cory, M.; Fairley, T. A.; Tidwell, R. R. Structure-activity studies of dicationically substituted bis-benzimidazoles against Giardia lamblia: correlation of antigiardial activity with DNA binding affinity and giardial topoisomerase II inhibition. Antimicrob. Agents Chemother., 1993, 37, 2668-2673.
19. Leepin, A.; Stüdli, A.; Brun, R.; Stephens, C. E.; Boykin, D. W.; Hemphill, A. Host cells participate in the in vitro effects of novel diamidine analogues against tachyzoites of the intracellular apicomplexan parasites Neospora caninum and Toxoplasma gondii. Antimicrob. Agents Chemother., 2008, 52, 1999-2008.
20. Upcroft, J. A.; Campbell, R. W.; Upcroft P. Quinacrine-resistant Giardia duodenalis. Parasitol., 1996, 112, 309-313
21. Shapiro, T. A.; Englund, P. T. Selective cleavage of kinetoplast DNA minicircles promoted by antitrypanosomal drugs. Proc. Natl. Acad. Sci. USA, 1990, 87, 950-954.
22. Kidwai, M.; Misra, P.; Kumar, P. The fluorinated quinolones. Curr. Pharmaceut. Design, 1998, 4, 101-118.
23. Sousa, M. C.; Poiares-da-Silva, J. The cytotoxic effects of ciprofloxacin in Giardia lamblia trophozoites. Toxicol. in Vitro, 2001, 15, 297-301.
24. He, D.; Wen J. F.; Chen, W. Q.; Lu, S. Q.; Xin, D.D. Identification, characteristic and phylogenetic analysis of type II DNA topoisomerase gene in Giardia lamblia. 2005. Cell Res., 15, 474-482.
25. Fichera, M.; Roos, D.S. A plastid organelle as a drug target in apicomplexan parasites. Nature, 1997, 390, 407-409.
26. Grant, P. A. A tale of histone modifications. Genome Biol., 2001, 2, REVIEWS0003.
27. Ho, L.; Crabtree, G., R. Chromatin remodelling during development. Nature, 2010, 463, 474-484.
28. Unoki, M.; Brunet, J.; Mousli, M. Drug discovery targeting epigenetic codes: the great potential of UHRF1, which links DNA methylation and histone modifications, as a drug target in cancers and toxoplasmosis. Biochem. Pharmacol., 2009, 78, 1279-1288.
29. Darkin-Rattray, S. J.; Gurnett, A. M.; Myers, R.W.; Dulski, P. M.; Crumley, T. M.; Allocco, J. J.; Cannova, C.; Meinke, P.T.; Colletti, S. L.; Bednarek, M. A.; Singh, S. B.; Goetz, M. A.; Dombrowski, A. W.; Polishook, J. D.; Schmatz, D. M. Apicidin: a novel antiprotozoal agent that inhibits parasite histone deacetylase. Proc. Natl. Acad. Sci. USA, 1996, 93, 13143-13147.
30. Singh, S. B.; Zink, D. L.; Liesch, J. M.; Mosley, R. T.; Dombrowski, A. W.; Bills, G. F.; Darkin-Rattray, S. J.; Schmatz, D. M.; Goetz, M. A. Structure and chemistry of apicidins, a class of novel cyclic tetrapeptides without a terminal alpha-keto epoxide as inhibitors of histone deacetylase with potent antiprotozoal activities. J. Org. Chem., 2002, 67, 815-825.
31. Bougdour, A.; Maubon, D.; Baldacci, P.; Ortet, P.; Bastien, O.; Bouillon, A.; Barale, J. C.; Pelloux, H.; Ménard, R.; Hakimi, M. A. Drug inhibition of HDAC3 and epigenetic control of differentiation in Apicomplexa parasites. J. Exp. Med., 2009, 206, 953-966.
32. Smith, A.T.; Livingston, M. R.; Mai, A.; Filetici, P.; Queener, S. F.; Sullivan, Jr W. J. Quinoline derivative MC1626, a putative GCN5 histone acetyltransferase (HAT) inhibitor, exhibits HATindependent activity against Toxoplasma gondii. Antimicrob. Agents Chemother., 2007, 51, 1109-1111.
33. Brodersen, D. E.; Clemons, W. M Jr.; Carter, A. P.; Morgan-Warren, R. J.; Wimberly, B. T.; Ramakrishnan, V. The structural basis for the action of the antibiotics tetracycline, pactamycin, and hygromycin B on the 30S ribosomal subunit. Cell, 2000, 103, 1143-1154.
34. Edlind, T. D. Susceptibility of Giardia lamblia to aminoglycoside protein synthesis inhibitors: correlation with rRNA structure. Antimicrob. Agents Chemother., 1989, 33, 484-488.
35. Fleige, T.; Soldati-Favre D. Targeting the transcriptional and translational machinery of the endosymbiotic organelle in apicomplexans. Curr. Drug. Targets, 2008, 9, 948-956.
36. Kirk-Mason, K. E.; Turner, M. J.; Chakraborty, P. R. Cloning and sequence of β-tubulin cDNA from Giardia lamblia. Nucl. Acids Res., 1988, 16, 2733.
37. Driscoll, M.; Dean E.; Reilly, E.; Bergholz E.; Chalfie, M. Genetic and molecular analysis of a Caenorhabditis elegans β;-tubulin that conveys benzimidazole sensitivity. J. Cell. Biol., 1989, 109, 2993-3003.
38. Katiyar, S. K.; Gordon, V. R.; Mclaughlin, G. L.; Edlind, T. D. Antiprotozoal activities of benzimidazoles and correlations with β- tubulin sequence. Antimicrob. Agents Chemother., 1994, 38, 2086-2090.
39. Kwa, M. S. G.; Veenstra, J. G.; Van Dijk, M.; Roos, M. H. β-ubulin genes from the parasite nematode Haemonchus contortus modulate drug resistance in Caenorhabditis elegans. J. Mol. Biol., 1995, 246, 500-516.
40. Satou, T.; Koga, M.; Matsuhashi, R.; Koike, K.; Tada, I.; Nikaido, T. Assay of nematocidal activity of isoquinoline alkaloids using third-stage larvae of Strongyloides ratti and S. venezuelensis. Vet. Parasitol., 2002, 104, 131-138.
41. Henriquez, F.; Ingram, P. R.; Muench, S. P.; Rice, D. W.; Roberts C. W. Molecular basis for the resistance of Acanthamoeba tubulins to all major classes of anti-tubulin compounds. Antimicrob. Agents Chemother., 2008, 52, 1133-1135.
42. Brehm, K.; Kronthaler, K.; Jura, H., Frosch, M. Cloning and characterization of beta-tubulin genes from Echinococcus multilocularis. Mol. Biochem. Parasitol., 2000, 107, 297-302.
43. Hemphill, A.; Müller, J. Alveolar and cystic echinococcosis: towards novel chemotherapeutical treatment options. J. Helminthol., 2009, 83, 99-111.
44. Brennan, G.P.; Fairweather, I.; Trudgett, A.; Hoey, E.; McCoy McConville, M.; Meaney, M.; Robinson, M.; McFerran, N.; Ryan, L.; Lanusse, C.; Mottier, L.; Alvarez, L.; Solana, H.; Virkel, G.; Brophy, P. M. Understanding triclabendazole resistance. Exp. Mol. Pathol., 2007, 82, 104-109.
45. Liotta, F, Siekierka J. J. Apicomplexa, trypanosoma and parasitic nematode protein kinases as antiparasitic therapeutic targets. Curr. Opin. Investig. Drugs, 2010, 11, 147-156.
46. Hammarton, T. C.; Mottram, J. C.; Doerig, C. The cell cycle of parasitic protozoa: potential for chemotherapeutic exploitation. Prog. Cell Cycle Res., 2003, 5, 91-101.
47. Wang, B. H.; Ternai, B.; Polya, G. M. Specific inhibition of cyclic AMP-dependent protein kinase by the antimalarial halofantrine and by related phenanthrenes. Biol. Chem. Hoppe Seyler, 1994, 375: 527-535.
48. Lugnier, C. Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents. Pharmacol. Ther., 2006, 109, 366-398.
49. Oberholzer, M.; Marti, G.; Baresic, M.; Kunz, S.; Hemphill, A.; Seebeck, T. The Trypanosoma brucei cAMP phosphodiesterases TbrPDEB1 and TbrPDEB2: flagellar enzymes that are essential for parasite virulence. FASEB J., 2007, 21, 720-731.
50. Wang, H.; Yan, Z.; Geng, J.; Kunz, S.; Seebeck, T.; Ke, H. Crystal structure of the Leishmania major phosphodiesterase LmjPDEB1 and insight into the design of the parasite-selective inhibitors. Mol. Microbiol., 2007, 66, 1029-1038.
51. Alonso, G. D.; Schoijet, A. C.; Torres, H. N.; Flawia, M. M. TcrPDEA1, a cAMPspecific phosphodiesterase with atypical pharmacological properties fromTrypanosoma cruzi. Mol. Biochem. Parasitol., 2007, 152, 72-79.
52. Savai, R.; Pullamsetti, S. S.; Banat, G. A.; Weissmann, N.; Ghofrani, H. A.; Grimminger, F.; Schermuly, R. T. Targeting cancer with phosphodiesterase inhibitors. Exp. Opin. Investig. Drugs, 2010, 19, 117-131.
53. Kunz, S.; Beavo, J. A.; D'Angelo, M.; Flawia, M. M.; Francis, S. H.; Johner, A.; Laxman, S.; Oberholzer, M.; Rascon, A.; Shakur, Y.; Wentzinger, L.; Zoraghi, R.; Seebeck, T. Cyclic nucleotide specific phosphodiesterases of the kinetoplastida: a unified nomenclature. Mol. Biochem. Parasitol., 2005, 145, 133-135.
54. Akiyama, T.; Ishida, J.; Nakagawa, S.; Ogawara, H.; Watanabe, S.; Itoh, N.; Shibuya, M.; Fukami, Y. Genistein, a specific inhibitor of tyrosine-specific protein kinases. J. Biol. Chem., 1987, 262, 5592-5595.
55. Gargala, G.; Le Goff, L.; Ballet, J. J.; Favennec, L.; Stachulski, A. V.; Rossignol, J.-F. Evaluation of new thiazolide/thiadiazolide derivatives reveals nitro group-independent efficacy against Cryptosporidium parvum in vitro development. Antimicrob. Agents Chemother., 2010, 54, 1315-1318
56. Morito, K.; Aomori, T.; Hirose, T. Interaction of phytoestrogens with estrogen receptors alpha and beta (II). Biol. Pharm. Bull., 2002, 25, 48-52.
57. di Paola, M.; Lorusso, M. Interaction of free fatty acids with mitochondria: coupling, uncoupling and permeability transition. Biochim. Biophys. Acta, 2006, 1757, 1330-1337.
58. Rayan, P.; Stenzel, D.; McDonnell, P. A. The effects of saturated fatty acids on Giardia duodenalis trophozoites in vitro. Parasitol. Res. 2005, 9, 191-200.
59. Anthony, J.-P.; Fyfe, L.; Smith, H. Plant active components-a resource for antiparasitic agents? Trends Parasitol., 2005, 21, 462-468.
60. Martin, R. J. Modes of action of anthelmintic drugs. Vet. J., 1997, 154, 11-34.
61. Blum, G.; Perkhofer, S.; Haas, H.; Schrettl, M.; Würzner, R.; Dierich, M.; Lass-Flörl, C. Potential basis for amphotericin B resistance in Aspergillus terreus. Antimicrob. Agents Chemother., 2008, 52, 1353-1355
62. Reuter, S., Merkle, M., Brehm, K., Kern, P.; Manfras B. Effect of amphotericin B on larval growth of Echinococcus multilocularis. Antimicrob. Agents Chemother., 2003a, 47, 620-625.
63. Reuter, S.; Buck, A.; Grebe, O.; Nüssle-Kügele, K.; Kern, P.; Manfras, B. Salvage treatment with amphotericin B in progressive human alveolar echinococcosis. Antimicrob. Agents Chemother.,2003, 47, 3586-3591.
64. Moore E. M.; Lockwood, D. N. Treatment of visceral leishmaniasis. J. Glob. Infect. Dis., 2010, 2, 151-158.
65. Keiser, J.; Chollet, J., Xiao, S. H.; Mei, J. Y.; Jiao, P. Y.; Utzinger, J.; Tanner, M. Mefloquine--an aminoalcohol with promising antischistosomal properties in mice. PLoS Negl. Trop. Dis., 2009, 3, e350.
66. Greenberg, R. M. Are Ca2+ channels targets of praziquantel action? Int. J. Parasitol., 2005, 35, 1-9.
67. Winter, R.W.; Kelly, J.X.; Smilkstein, M.J.; Dodean, R.; Hinrichs, D.; Riscoe, M.K. Antimalarial quinolones: synthesis, potency, and mechanistic studies. Exp. Parasitol., 2008, 118, 487-497.
68. Goodman, C. D.; McFadden, G. I. Fatty acid biosynthesis as a drug target in apicomplexan parasites. Curr. Drug Targets, 2007, 8, 15-30.
69. Waller, R. F.; Keeling, P. J.; Donald, R. G.; Striepen, B.; Handman, E.; Lang-Unnasch, N.; Cowman, A. F.; Besra, G. S.; Roos, D. S.; McFadden, G., I. Nuclear-encoded proteins target to the plastid in Toxoplasma gondii and Plasmodium falciparum. Proc. Natl. Acad. Sci. USA, 1998, 95,12352-12327.
70. Zhu, G.; Marchewka, M. J.; Woods, K. M.; Upton, S. J.; Keithly, J S. Molecular analysis of a Type I fatty acid synthase in Cryptosporidium parvum. Mol. Biochem. Parasitol., 2005, 105, 253-260.
71. Gottstein, B.; Razmi, G. R.; Ammann, P.; Sager, H.; Müller, N. Toltrazuril treatment to control diaplacental Neospora caninum transmission in experimentally infected pregnant mice. Parasitology, 2005, 130, 41-48.
72. Strohbusch, M.; Müller, N.; Hemphill, A.; Krebber, R.; Greif, G.; Gottstein, B. Toltrazuril treatment of congenitally acquired Neospora caninum infection in newborn mice Parasitol. Res., 2009, 104, 1335-1343.
73. Härdi, C.; Hässig, M.; Sager, H.; Greif, G.; Staubli, D.; Gottstein, B. Humoral immune reaction of newborn calves congenitally infected with Neospora caninum and experimentally treated with toltrazuril. Parasitol. Res., 2006, 99, 534-540.
74. Upcroft, J. A.; Upcroft, P. Drug resistance and Giardia. Parasitol. Today, 1993, 9, 187-190.
75. Boreham, P. F.; Philips, R. E.; Shepherd, R. W. Altered uptake of metronidazole in vitro by stocks of Giardia intestinalis with different drug sensitivities. Trans. R. Soc. Trop. Med. Hyg., 1988, 82, 104-106.
76. Upcroft, P.; Upcroft, J. A. Drug targets and mechanisms of resistance in the anaerobic protozoa. Clin. Microbiol. Rev., 2001, 14, 150-164.
77. Horner, D. S.; Hirt, R. P.; Embley, T. M. A single eubacterial origin of eukaryotic pyruvate:ferredoxin oxidoreductase genes: Implications for the evolution of anaerobic eukaryotes. Mol. Biol. Evol., 1999, 16, 1280-1291.
78. Sisson, G.; Goodwin, A.; Raudonikiene, A.; Hughes, N. J.; Mukhopadhyay A. K.; Berg, D. A.; Hoffman, P. S. Enzymes associated with reductive activation and action of nitazoxanide, nitrofurans, and metronidazole in Helicobacter pilori. Antimicrob. Agents Chemother., 2002, 46, 2116-2123.
79. Leitsch, D.; Kolarich D.; Binder, M.; Stadlmann, J.; Altmann, F.; Duchêne, M. Trichomonas vaginalis: metronidazole and other nitroimidazole drugs are reduced by the flavin enzyme thioredoxin reductase and disrupt the cellular redox system. Implications for nitroimidazole toxicity and resistance. Mol Microbiol., 2009, 72, 518-536.
80. Argüello-García, R.; Cruz-Soto, M.; Romero-Montoya, L.; Ortega- Pierres, G. In vitro resistance to 6-nitroimidazoles and benzimidazoles in Giardia duodenialis: variability and variation in gene expression. Infect. Genet. Evol., 2009, 9, 1057-1064.
81. Asawamahasakda, W.; Ittarat, I.; Pu, Y.M.; Ziffer, H.; Meshnick, S.R. Reaction of antimalarial endoperoxides with specific parasite proteins. Antimicrob. Agents Chemother., 1994, 38, 1854-1858.
82. Cui, L.; Su, X. Z. Discovery, mechanisms of action and combination therapy of artemisinin. Expert Rev. Anti Infect. Ther., 2009, 7, 999-1013.
83. Kim, J. T.; Park, J. Y.; Seo, H. S.; Oh, H. G.; Noh, J. W.; Kim, J. H.; Kim, D. Y.; Youn, H. J. In vitro antiprotozoal effects of artemisinin on Neospora caninum. Vet. Parasitol., 2002,103, 53-63.
84. Wang, J.; Huang, L.; Li, J.; Fan, Q.; Long, Y.; Li, Y.; Zhou, B. Artemisinin directly targets malarial mitochondria through its specific mitochondrial activation. PLoS One, 2010, 5, e9582.
85. Adagu, I. S. Nolder, D.; Warhurst, D.; Rossignol, J.-F. In vitro activity of nitazoxanide and related compounds against isolates of Giardia intestinalis, Entamoeba histolytica and Trichomonas vaginalis. J. Antimicrob. Chemother., 2002, 49, 103-111.
86. Müller, J.; Rühle, G.; Müller, N.; Rossignol, J.-F.; Hemphill A. In vitro effects of thiazolides on Giardia lamblia WB C6 cultured axenically and in co-culture with Caco2 cells. Antimicrob. Agents Chemother., 2006, 50, 162-170.
87. Müller, J.; Wastling, J.; Sanderson, S.; Müller, N.; Hemphill, A. A novel Giardia lamblia nitroreductase, GlNR1, interacts with nitazoxanide and other thiazolides. Antimicrob. Agents Chemother., 2007. 51, 1979-1986.
88. Hemphill, A.; Vonlaufen, N.; Naguleswaran, N. Cellular and immunological basis of the host-parasite relationship during infection with Neospora Caninum. Parasitol., 2006,133, 261-278
89. Hemphill, A.; Müller, J.; Esposito, M. Nitazoxanide, a broadspectrum thiazolide anti-infective agent for the treatment of gastrointestinal infections. Exp. Opin. Pharmacother., 2006, 7, 953-964.
90. Hemphill, A.; Müller, N.; Müller, J. Structure-function relationship of thiazolides, a novel class of anti-parasitic drugs, investigated in intracellular and extracellular protozoan parasites and larval-stage cestodes. Antiinf. Agents Med. Chem., 2007, 6, 273-282.
91. Cortes, H. C. E.; Müller, N.; Esposito, M.; Leitão, A.; Naguleswaran, A.; Hemphill, A. In vitro efficacy of nitro- and bromothiazolyl-salicylamide compounds (thiazolides) against Besnoitia besnoiti infection in Vero cells. Parasitology, 2007, 134, 975-985.
92. Müller, J; Naguleswaran, A.; Müller, N.; Hemphill, A. Neospora caninum: Functional inhibition of protein disulfide isomerase by the broad-spectrum anti-parasitic drug nitazoxanide and other thiazolides. Exp. Parasitol., 2008, 118, 80-88.
93. Müller, J.; Sidler, D.; Nachbur, U.; Wastling, J.; Brunner, T.; Hemphill, A. Thiazolides inhibit growth and induce glutathione-Stransferase pi (GSTP1)-dependent cell death in human colon cancer cells. Int. J. Cancer, 2008, 123, 1797-1806.
94. Liebau, E.; Müller, V.; Lucius, R.; Walter, R. D.; Henkle-Dührsen, K. Molecular cloning, expression and characterization of a recombinant glutathione-S-transferase from Echinococcus multilocularis. Mol. Biochem. Parasitol., 1996, 77, 49-56.
95. Fernandez, V.; Chalar, C.; Martinez, C.; Musto, H.; Zaha, A.; Fernandez, C. Echinococcus granulosus: molecular cloning and phylogenetic analysis of an inducible glutathione-S-transferase. Exp. Parasitol., 2000, 96, 190-194.
96. Brocks, D. R.; Mehvar, R. Stereoselectivity in the pharmacodynamics and pharmacokinetics of the chiral antimalarial drugs. Clin. Pharmacokinet., 2003, 42, 1359-1382.
97. Oliveira, M. F.; d'Avila, J. C.; Tempone, A. J.; Soares, J. B.; Rumjanek, F. D.; Ferreira-Pereira, A.; Ferreira, S. T.; Oliveira, P. L. Inhibition of heme aggregation by chloroquine reduces Schistosoma mansoni infection. J. Infect. Dis., 2004, 190, 843-852.
98. Keiser, J.; Chollet, J.; Xiao, S. H.; Mei, J. Y.; Jiao, P. Y.; Utzinger, J.; Tanner, M. Mefloquine--an aminoalcohol with promising antischistosomal properties in mice. PLoS Negl. Trop. Dis., 2009, 3, e350.
99. Wiesner, J.; Reichenberg, A.; Heinrich, S.; Schlitzer, M.; Jomaa H. The plastid-like organelle of apicomplexan parasites as drug target. Curr. Pharm. Des., 2008, 14, 855-871.
100. Volkmann, L.; Fischer, K.; Taylor, M.; Hoerauf, A. Antibiotic therapy in murine filariasis (Litomosoides sigmodontis): comparative effects of doxycycline and rifampicin on Wolbachia and filarial viability. Trop. Med. Int. Health, 2003, 8, 392-401.